By running Rosetta@home on your computer when you're not using it you will speed up and extend our efforts to design new proteins and to predict their 3-dimensional shapes. Proteins are the molecular machines and building blocks of life. You can read more about protein folding and design here.

Follow us on Twitter: @rosettaathome

Rosetta@home is not for profit.

Join Ralph@home to help improve this project.

Sir Stooper
I am a [insert fake age here] year old [complimentary adjective] male who [likes/dislikes (circle one)] dogs. I have been shrubbing for [current year...

Predictor of the day: Congratulations to 2buiy5RiX3bN8JBr2yuiTCdV5yLJ (Team Gridcoin) for predicting the lowest energy structure for workunit rb_02_26_22117....
1 Mar 2022, 0:00:00 UTC · Discuss

---

... more

Predictor of the day is available as an RSS feed  

Rosetta@home Update

First, we’d like to thank all our contributors who have supported and continue to contribute to our scientific projects through Rosetta@home. We want to update you on the status of Rosetta@home projects and our future plans.

With the advancement of AI models like AlphaFold and RosettaFold for protein structure predictions, Rosetta@home has been less used for this purpose. However, researchers are now utilizing Rosetta@home for small molecule and peptide designs, where even the current state-of-the-art AI models struggle due to limitations in generalizability to novel small molecules and non-canonical peptides.

Recently, we have developed a virtual screening protocol in Rosetta, named RosettaVS, for small molecule drug discovery. This work has been published in Nature Communications (https://doi.org/10.1038/s41467-024-52061-7), demonstrating that RosettaVS is one of the best physics-based virtual screening protocols. Combined with deep learning techniques, it can effectively screen multi-billion compound libraries and discover novel compounds for pharmaceutical targets.

While deep learning models like AlphaFold and RosettaFold can predict canonical peptide structures, they cannot handle peptides with non-canonical amino acids or mixed chirality. The physics-based force field in Rosetta has specialized terms to simulate these amino acids. Rosetta will be used to sample hundreds of thousands of different conformations of the designed peptide to validate the structure.

Looking ahead, Rosetta@home will be an invaluable platform for large-scale virtual screening and peptide simulations for drug discovery. We plan to launch more virtual screening jobs and peptide simulations on Rosetta@home in the near future.

Thank you!

4 Mar 2025, 4:50:22 UTC · Discuss

---

COVID-19 vaccine with IPD nanoparticles wins full approval abroad



The IPD is excited to announce it's first designed protein medicine with full approval abroad.

Congrats and thank you to all Rosetta@home contributors! The computing you have provided has greatly aided in de novo protein design challenges such as vaccine development leading to breakthroughs like this.

For more information you can visit the IPD vaccine news post.

A video is also available here.


From the IPD news site:

• Clinical testing found the vaccine outperforms Oxford/AstraZeneca’s

• The protein-based vaccine, now called SKYCovione, does not require deep freezing

• University of Washington to waive royalty fees for the duration of the pandemic

• South Korea to purchase 10 million doses for domestic use

A vaccine for COVID-19 developed at the University of Washington School of Medicine has been approved by the Korean Ministry of Food and Drug Safety for use in individuals 18 years of age and older. The vaccine, now known as SKYCovione, was found to be more effective than the Oxford/AstraZeneca vaccine sold under the brand names Covishield and Vaxzevria.

SK bioscience, the company leading the SKYCovione’s clinical development abroad, is now seeking approval for its use in the United Kingdom and beyond. If approved by the World Health Organization, the vaccine will be made available through COVAX, an international effort to equitably distribute COVID-19 vaccines around the world. In addition, the South Korean government has agreed to purchase 10 million doses for domestic use.

The Seattle scientists behind the new vaccine sought to create a ‘second-generation’ COVID-19 vaccine that is safe, effective at low doses, simple to manufacture, and stable without deep freezing. These attributes could enable vaccination at a global scale by reaching people in areas where medical, transportation, and storage resources are limited.

“We know more than two billion people worldwide have not received a single dose of vaccine,” said David Veesler, associate professor of biochemistry at UW School of Medicine and co-developer of the vaccine. “If our vaccine is distributed through COVAX, it will allow it to reach people who need access.”

The University of Washington is licensing the vaccine technology royalty-free for the duration of the pandemic.

Congrats and thank you again to all R@h contributors!

6 Jul 2022, 18:27:59 UTC · Discuss

---

Thank you!

We'd like to thank everyone who has contributed and continues to contribute to this project, and would like to remind everyone that there may be periods of down time while we are preparing for future large scale batches of jobs and analyzing results. We greatly appreciate your contributions which are vitally important to our ongoing research.

Thank you!

5 Nov 2020, 20:16:29 UTC · Discuss

---

Coronavirus update from David Baker. Thank you all for your contributions!

Here is a short video of David Baker describing some exciting results from de novo designs targeting SARS-Cov-2.

Thank you all for your contributions to this research! Although R@h was not directly used for the work described in the publication (link provided below), R@h was used for designing relevant scaffolds. Additionally, there are currently many similar designs that bind SARS-Cov-2 and related targets that were engineered using R@h.

https://www.youtube.com/embed/ODEIN5V3yLg

More information is available from the publication, De novo design of picomolar SARS-CoV-2 mini protein inhibitors.



21 Sep 2020, 23:16:33 UTC · Discuss

---

Switch to using SSL (Secure Socket Layer)

We updated our project to use SSL. The project URL has thus been changed to https://boinc.bakerlab.org/rosetta. You can reattach the project using this updated URL at your convenience. Please post any issues regarding this update in the discussion thread.

1 May 2020, 21:25:30 UTC · Discuss

---

... more

News is available as an RSS feed